In summary, while the heightened N-cad expression observed in the IMPC component within our cohort supports its metastatic potential, breast cancer cases within this group do not exhibit a shorter expected survival compared to those with IBC-NST. The gene discussed is CDH2; the disease is breast carcinoma.